Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom 17-Jan-2023 / 06:56 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

GENEVA, JAN. 17, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company identifying, developing and commercializing novel, patent protected products in select specialty, rare and ultra-rare disease areas, announced independent institutional review board (IRB) approval for the protocol  of an investigator-initiated trial to evaluate RLF-TD011 as an adjunctive treatment for patients diagnosed with cutaneous t-cell lymphoma (CTCL). The study will evaluate the effect of RLF-TD011, a patent-protected hypochlorous acid topical spray, on the microbiome of CTCL skin lesions and determine tolerability, symptom improvement, and potential for reducing lesion size and skin disease activity.

The study will enroll participants at Northwestern department of dermatology in Chicago. Microbiome assessments will be performed under the leadership of co-principal investigator Alan Zhou, M.D., MSc., fellow of the American Academy of Dermatology and assistant professor of dermatology at Northwestern University.

CTCL is a rare, heterogeneous group of non-Hodgkin’s lymphomas in which malignant t-cells infiltrate the skin. Advanced CTCL lesions harbor Staphylococcus aureus, which release toxins that stimulate malignant cells and drive disease progression. This often leads to recurrent skin infections with a high risk for sepsis and death.

“Treatment of advanced CTCL remains a challenge, with five-year disease-specific survival rates ranging from 70 percent for early stage to 24 percent for advanced disease, with the greatest mortality stemming from bacterial infections,” said Dr. Alan Zhou. “This proof-of-concept clinical study will look at the microbiome changes and clinical improvement in 30 patients over an eight-week study period. We will evaluate how the bactericidal activity of this unique hypochlorous acid skin spray, previously shown to kill methicillin-sensitive and methicillin-resistant Staphylococcus aureus, as well as Pseudomonas aeruginosa—could improve the CTCL microbiome to potentially decrease pruritus, erythema, scaling, lesion size and overall skin disease activity, with the goal of delaying disease progression and reducing death.”